Skip to Main Content
Contribute Try STAT+ Today

An experimental medicine from AstraZeneca and Amgen significantly reduced the frequency of asthma attacks when added to standard treatment, achieving the goals of a late-stage clinical trial involving patients with severe asthma, the companies announced Tuesday.

The AstraZeneca/Amgen drug — a once-monthly antibody injection called tezepelumab — was also shown to be effective in curbing asthma attacks in patients with low levels of eosinophils, a type of inflammatory white blood cell. This outcome could prove to be an important distinction because currently approved antibody treatments for severe asthma like Regeneron Pharma’s Dupixent work poorly in low-eosinophil asthma patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.